Growth Factor Cocktail Shows Promise in Reversing Late-Stage Anthrax

A new study published in Nature Microbiology offers hope for treating anthrax beyond the current "point of no return." Researchers at the University of Pittsburgh have demonstrated that a combination of growth factors can reverse cellular damage in mice with advanced anthrax, potentially paving the way for new treatments in humans.

Anthrax, caused by the bacterium Bacillus anthracis, is typically treatable in its early stages. However, once the disease progresses past a certain point, usually within a few days, current treatments become ineffective, leading to almost certain death. The study's senior author, Shihui Liu, emphasized the importance of developing new approaches for treating later stages of the disease, particularly given the potential threat of anthrax as a bioweapon.

The research focused on the mechanisms by which anthrax's lethal toxin causes cellular damage. The toxin inactivates enzymes called MEKs by cleaving off one of their ends, disrupting crucial cellular pathways. The team discovered that anthrax must inactivate both the ERK and p38 pathways to kill its host.

In a breakthrough finding, the researchers demonstrated that a combination of three growth factors could reactivate the ERK pathway in mice and human cells exposed to lethal toxin or B. anthracis. This treatment effectively brought the cells back from what was previously considered the point of no return.

Dr. Liu expressed surprise at this discovery, stating, "Because lethal toxin breaks MEK proteins by clipping off their ends, we thought that this cellular damage was irreversible. So we were really surprised to find that specific growth factors were able to reactivate the ERK pathway and rescue the cell."

While these results are promising, the researchers acknowledge that further work is needed to optimize the treatment for human use. Different cell types may require different growth factors to activate the ERK pathway effectively. Nevertheless, this study represents a significant step forward in the potential treatment of late-stage anthrax.